Sinopharm's Wuhan unit reports 72.5% efficacy for Covid shot, seeks approval in China
The company has filed a formal application to China’s National Medical Products Administration for approval for public use of the vaccine, it said in a statement on its website
A sign of Sinopharm is seen at the 2020 China International Fair for Trade in Services (CIFTIS), following the COVID-19 outbreak, in Beijing, China September 5, 2020. REUTERS/Tingshu Wang
The Sinopharm unit Wuhan Institute Of Biological Products Co said on Wednesday its Covid-19 vaccine had shown an efficacy rate of 72.51% against the disease in Phase III clinical trials, based on interim analysis.
The company has filed a formal application to China's National Medical Products Administration for approval for public use of the vaccine, it said in a statement on its website.
Keep updated, follow The Business Standard's Google news channel
